1-4 of 4
Jessica Alfredsson
Close
Sort by
Journal Articles

Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer

Nina Mohell, PhD, Charlotta Liljebris, PhD, Jessica Alfredsson, PhD, Ylva Lindman, MSc, Maria Uustalu, MSc, Thomas Uhlin, BSc, Mats R.H. Linderholm, MD, PhD, Klas G. Wiman, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1806.
https://doi.org/10.1182/blood.V116.21.1806.1806
Published: 2010
Journal Articles

Further Preclinical Studies with APR-246, a Novel Anticancer Compound Currently in Clinical Trials for Hematological Malignancies and Prostate Cancer.

Nina Mohell, PhD, Charlotta Liljebris, PhD, Jessica Alfredsson, PhD, Ylva Lindman, MSc, Maria Uustalu, MSc, Klas G Wiman, PhD, MD, Thomas Uhlin, BSc
Journal: Blood
Blood (2009) 114 (22): 3773.
https://doi.org/10.1182/blood.V114.22.3773.3773
Published: 2009
Journal Articles

NFAT but not NF-κB is critical for transcriptional induction of the prosurvival gene A1 after IgE receptor activation in mast cells

Erik Ullerås, Mats Karlberg, Christine Möller Westerberg, Jessica Alfredsson, Steve Gerondakis, Andreas Strasser, Gunnar Nilsson
Journal: Blood
Blood (2008) 111 (6): 3081–3089.
https://doi.org/10.1182/blood-2006-10-053371
Published: 2008
Journal Articles

Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim

Christine Möller, Jessica Alfredsson, Maria Engström, Hanna Wootz, Zou Xiang, Johan Lennartsson, Jan-Ingvar Jönsson, Gunnar Nilsson
Journal: Blood
Blood (2005) 106 (4): 1330–1336.
https://doi.org/10.1182/blood-2004-12-4792
Published: 2005